Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I Study of VV116 in Healthy Chinese Volunteers
NCT05227768Phase 1Completed
- Sponsor
- Vigonvita Life Sciences
- Start
- Nov 2021
- Primary completion
- Jan 2022
- Modality
- Orthosteric Ligands, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of deuremidevir in coronavirus disease 2019 (COVID-19) (5 cohorts), sponsored by Vigonvita Life Sciences. Primary endpoints: Incidence of Treatment-Emergent Adverse Events, Time to Maximum Plasma Concentration and 2 more. Started Nov 2021; status: completed.
02
Drugs
deuremidevir
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05227768.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05227768.